ArticleMicrobial cell factories2011
Post-production protein stability: trouble beyond the cell factory.
Article in Microbial cell factories, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy.Cell biochemistry and biophysics · 2025Article
- Target-template relationships in protein structure prediction and their effect on the accuracy of thermostability calculations.Protein science : a publication of the Protein Society · 2023Article
- Influence of the mRNA initial region on protein production: a case study using recombinant detoxified pneumolysin as a model.Frontiers in bioengineering and biotechnology · 2023Article
- Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2.PloS one · 2023Article
- Structure-Activity Relationship of the Dimeric and Oligomeric Forms of a Cytotoxic Biotherapeutic Based on Diphtheria Toxin.Biomolecules · 2022Article
- Recent Advancements and Future Perspectives of Microalgae-Derived Pharmaceuticals.Marine drugs · 2021Review
- Article
- Overexpression and characterization of a novel GH16 β-agarase (Aga1) from Cellulophaga omnivescoria W5C.Biotechnology letters · 2020Article
- Innovative approach for improved rFVIII concentrate.European journal of haematology · 2014Review
- Chemical glycosylation of cytochrome c improves physical and chemical protein stability.BMC biochemistry · 2014Article
- To fuse or not to fuse: what is your purpose?Protein science : a publication of the Protein Society · 2013Review
- Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions.Pharmaceutical research · 2013Article
- Article
- Biocatalytic potential of laccase-like multicopper oxidases from Aspergillus niger.Microbial cell factories · 2012Article
- Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.International journal of nanomedicine · 2012Article
- Biophysical characterization of Met-G-CSF: effects of different site-specific mono-pegylations on protein stability and aggregation.PloS one · 2012Article
- The Aspergillus niger multicopper oxidase family: analysis and overexpression of laccase-like encoding genes.Microbial cell factories · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Being protein function a conformation-dependent issue, avoiding aggregation during production is a major challenge in biotechnological processes, what is often successfully addressed by convenient upstream, midstream or downstream approaches. Even when obtained in soluble forms, proteins tend to aggregate, especially if stored and manipulated at high concentrations, as is the case of protein drugs for human therapy. Post-production protein aggregation is then a major concern in the pharmaceutical industry, as protein stability, pharmacokinetics, bioavailability, immunogenicity and side effects are largely dependent on the extent of aggregates formation. Apart from acting at the formulation level, the recombinant nature of protein drugs allows intervening at upstream stages through protein engineering, to produce analogue protein versions with higher stability and enhanced therapeutic values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.